Anagrelide Hydrochloride selectively inhibits megakaryocyte maturation to reduce platelet production, making it a targeted therapy for essential thrombocythaemia and other myeloproliferative disorders. Simson Pharma's Anagrelide Hydrochloride reference standard and impurities support stability-indicating method development for this haematology-focused therapeutic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Anagrelide Hydrochloride Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.